Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 07:00 ET | Source: Herantis Pharma plc

Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096

FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...
June 02, 2026 05:57 ET | Source: Herantis Pharma plc

Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096

FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...
October 30, 2025 05:00 ET | Source: Alethio Therapeutics

Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)

Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cellsAdvancing AT-01, a first-in-class...
January 10, 2022 08:00 ET | Source: Halo Biosciences

Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022

SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Halo Biosciences, a clinical stage biopharmaceutical company today announced that its Chief Executive Officer, Anissa Kalinowski, MSc, MBA, will...
December 20, 2018 08:00 ET | Source: Retrophin, Inc.

Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN

SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and...